You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

  • Technology appraisal guidance
  • Reference number: TA715
  • Published:  14 July 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Assessment report sent for information
  5. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 172 KB)

    Published:
    14 July 2021
  • Register of interests (PDF 159 KB)

    Published:
    14 July 2021

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 319 KB)

    Published:
    10 June 2021
  • Committee papers (PDF 824 KB)

    Published:
    10 June 2021

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF version) (PDF 328 KB)

    Published:
    31 March 2021
  • Appraisal consultation document (online commenting)

  • Committee papers (PDF 2.2 MB)

    Published:
    31 March 2021
  • Public committee slides (PDF 510 KB)

    Published:
    31 March 2021

Assessment report sent for information

  • Assessment report (MSWord 356 KB)

    Published:
    14 January 2021

Invitation to participate

  • Final scope (PDF 228 KB)

    Published:
    03 September 2020
  • Final stakeholder list (PDF 167 KB)

    Published:
    03 September 2020
Back to top